MedTrace Logo

Pharmacokinetics of BF2.649 in Renal Impairment

NCT01619033 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-04-12

No results posted yet for this study

Summary

This is an open, parallel group study in subjects with normal renal function compared to those with renal dysfunction.

Conditions

  • Renal Impairment

Interventions

DRUG

BF2.649

single dose 20 mg

Sponsors & Collaborators

Principal Investigators

  • Claire POUTEIL-NOBLE, MD · Nephrologie, Centre Hospitalier Lyon Sud

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01619033 on ClinicalTrials.gov